… may be different in Parkinson’s disease (PD) patients compared to controls, at least in the cerebrospinal fluid. Thus … in accessible body fluids may serve as a biomarker for PD. However, in order to qualify human alpha-synuclein protein … Washington … Linked Efforts to Accelerate Parkinson’s Solutions …

… Objective/Rationale: GDNF, a naturally-occurring growth factor capable of protecting and promoting the survival of … has great potential as a treatment for Parkinson’s disease. However, the delivery of GDNF to the brain has proven to be … may be developed as a therapy for patients. Anticipated Outcome: Before testing in humans, we must confirm that …

… spinal fluid, urine and brain images are already beginning to provide scientists with key insights into the search for a biomarker for PD. In this podcast, MJFF … of the original study, PPMI is now expanding. Learn how you can help!    Nate Herpich …

… up for Fox Trial Finder, Dan Andrews answered simply, “To find a cure.” Dan, who was diagnosed with Parkinson's … to find a cure and his active involvement in the PD community. Getting people into clinical trials, Dan believes, is a …

… of levodopa, the gold standard treatment for Parkinson's motor symptoms. The results of the FDA review will be … and only available therapy specifically designed to target levodopa-induced dyskinesia. Developed by Adamas … amantadine (ADS-5102) that is taken once daily at bedtime. Compared with a shorter-acting form of amantadine already on …

…              Magnetic resonance imaging (MRI) is a common tool used to diagnose or evaluate brain diseases such as … disease. Typically, MRI images are read by a radiologist. However, imaging techniques often provide large amounts of … Access to Data and Biospecimens …